한글목차

레닌·안지오텐신계(RAS) 작용제 시장 규모는 최근 현저한 성장을 보이고 있습니다. 2025년 61억 1,000만 달러에서 2026년에는 64억 4,000만 달러에 이르고, CAGR 5.5%로 성장할 전망입니다. 지난 몇 년간의 성장 요인으로는 고혈압 환자의 높은 유병률, 고령화 인구 증가, ACE 억제제의 보급 확대, 심혈관 질환 검진 증가, 제네릭 의약품의 저렴한 가격 등이 꼽힙니다.

레닌·안지오텐신계(RAS) 작용제 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 79억 6,000만 달러에 이르고, CAGR은 5.4%를 나타낼 전망입니다. 예측 기간 동안의 성장에는 만성 신장 질환의 부담 증가, 심대사 질환 치료제에 대한 수요, 치료 순응도 향상, 신흥 시장 확대, 병용요법 승인 등이 주요 요인으로 작용할 것으로 보입니다. 예측 기간의 주요 동향으로는 항고혈압제 병용요법 증가, 장기지속형 심혈관 약물의 성장, 신보호 요법에 대한 관심 증가, 제네릭 RAS 약물의 생산 확대, 고정용량 복합제로의 전환 등을 꼽을 수 있습니다.

고혈압 발생률 증가는 레닌-안지오텐신계(RAS) 작용제 시장 확대를 촉진할 것으로 예측됩니다. 고혈압은 동맥벽에 가해지는 혈압이 지속적으로 과도하게 높아진 상태를 말합니다. 식습관의 악화, 특히 소금과 가공식품이 많은 식습관은 혈압을 상승시키고 심혈관계에 부담을 주기 때문에 고혈압의 발병률은 증가하는 추세입니다. 레닌-안지오텐신계(RAS) 작용제는 혈관을 수축시키고 체액 저류를 촉진하는 호르몬인 안지오텐신 II의 작용을 억제하여 혈압을 조절하고, 혈관 이완과 혈압 강하를 촉진하여 고혈압과 싸우는 약제입니다. 예를 들어, 2025년 9월 스위스에 본부를 둔 국제기구인 세계보건기구(WHO)는 2024년 기준 전 세계 30세에서 79세 사이의 성인 중 약 14억 명(동 연령대의 약 33%)이 고혈압을 앓고 있다고 보고했습니다. 따라서 고혈압에 대한 부담이 증가하면서 레닌-안지오텐신계(RAS) 작용제 수요를 촉진하고 있습니다.

레닌-안지오텐신계(RAS) 작용제 시장의 주요 기업들은 효과 개선, 부작용 감소, 환자의 복약 순응도 향상, 고혈압, 심부전, 신장질환 등의 증상 대응을 위해 안지오텐신 전환효소(ACE) 억제제를 포함한 혁신적인 RAS 억제제 개발에 우선순위를 두고 있습니다. 개발하고 있습니다. 안지오텐신 전환효소(ACE) 억제제는 혈관을 수축시키는 화합물인 안지오텐신 II로 전환하는 효소를 억제하여 혈압을 낮추는 약제입니다. 예를 들어, 2023년 11월 영국에 본사를 둔 제약회사 프로베카(Proveca)는 유럽연합 집행위원회로부터 소아용 승인(PUMA)을 위한 보조금을 획득했습니다. 대상은 생후부터 18세 미만의 소아 심부전 치료제로 승인된 아캄멜디(에날라프릴 말레인산염) 경구붕해정입니다. 안지오텐신 전환효소(ACE) 억제제인 악멜디는 안지오텐신 전환효소(ACE)를 억제하여 소아 환자의 심부전을 관리합니다. 이는 안지오텐신 I에서 안지오텐신 II로의 전환을 차단하여 혈관을 이완시키고 혈류를 촉진하여 심장의 부담을 줄입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병(M&A)

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

RAS-acting agents are a group of drugs that control blood pressure, fluid levels, and blood vessel tone by acting on key elements of the renin-angiotensin system, which is vital for heart and kidney health. Doctors often prescribe them for hypertension, heart failure, and chronic kidney disease because they either prevent angiotensin II formation or block its actions on blood vessels.

The primary drug categories among renin-angiotensin-system (RAS)-acting agents include angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), renin inhibitors, aldosterone antagonists, and additional types. Angiotensin-converting enzyme (ACE) inhibitors are drugs that inhibit the enzyme converting angiotensin I to angiotensin II, a compound that constricts blood vessels and raises blood pressure. They treat conditions like hypertension, heart failure, chronic kidney disease, diabetic nephropathy, and coronary artery disease, and reach patients via hospital pharmacies, retail pharmacies, online pharmacies, and specialty clinics serving end users such as hospitals, research institutes, pharmaceutical companies, and more.

Tariffs have affected the renin-angiotensin system acting agents market by increasing the cost of imported APIs, intermediates, and formulation excipients used in cardiovascular drug manufacturing. These impacts have been most pronounced in branded ACE inhibitors and ARBs, particularly in north america and europe where API sourcing is globally diversified. Asia-pacific producers have experienced pricing pressures due to raw material imports. However, tariffs have supported domestic generic manufacturing and localized API synthesis, enhancing long-term supply security.

The renin-angiotensin-system (ras)-acting agents market research report is one of a series of new reports from The Business Research Company that provides renin-angiotensin-system (ras)-acting agents market statistics, including renin-angiotensin-system (ras)-acting agents industry global market size, regional shares, competitors with a renin-angiotensin-system (ras)-acting agents market share, detailed renin-angiotensin-system (ras)-acting agents market segments, market trends and opportunities, and any further data you may need to thrive in the renin-angiotensin-system (ras)-acting agents industry. This renin-angiotensin-system (ras)-acting agents market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The renin-angiotensin-system (ras)-acting agents market size has grown strongly in recent years. It will grow from $6.11 billion in 2025 to $6.44 billion in 2026 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to high hypertension prevalence, aging population growth, widespread ACE inhibitor adoption, increased cardiovascular screening, affordability of generic drugs.

The renin-angiotensin-system (ras)-acting agents market size is expected to see strong growth in the next few years. It will grow to $7.96 billion in 2030 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to chronic kidney disease burden, demand for cardiometabolic drugs, improved treatment adherence, expansion in emerging markets, combination therapy approvals. Major trends in the forecast period include increasing use of combination antihypertensive therapies, growth of long-acting cardiovascular drugs, rising focus on renal protection therapies, expansion of generic RAS drug production, shift toward fixed-dose combinations.

The rising incidence of hypertension is anticipated to fuel expansion in the market for renin-angiotensin system (RAS)-acting agents. Hypertension, known as high blood pressure, is a persistent condition where the pressure of blood against artery walls remains excessively elevated. Rates of hypertension are climbing due to poor dietary habits, especially those rich in salt and processed foods, which raise blood pressure and burden the cardiovascular system. Renin-angiotensin system (RAS)-acting agents combat hypertension by controlling blood pressure via blockade of angiotensin II, a hormone that narrows blood vessels and promotes fluid buildup, thus encouraging vessel relaxation and blood pressure reduction. For instance, in September 2025, the World Health Organization-a Switzerland-based intergovernmental body-reported that roughly 1.4 billion adults aged 30-79 globally had hypertension in 2024, representing about 33% of this demographic. Hence, the growing burden of hypertension is spurring demand for renin-angiotensin system (RAS)-acting agents.

Major companies in the renin-angiotensin system (RAS)-acting agents market are prioritizing the development of innovative renin-angiotensin system (RAS) inhibitors, including angiotensin-converting enzyme (ACE) inhibitors, to boost effectiveness, reduce adverse effects, enhance patient adherence, and address conditions like hypertension, heart failure, and kidney disorders. An angiotensin-converting enzyme (ACE) inhibitor is a drug that reduces blood pressure by inhibiting the enzyme responsible for transforming angiotensin I into angiotensin II, a compound that constricts blood vessels. For example, in November 2023, Proveca Ltd., a UK-based pharmaceutical firm, secured a grant from the European Commission for pediatric use marketing authorization (PUMA) of Aqumeldi (enalapril maleate) orodispersible tablets, approved for treating heart failure in children from birth to under 18 years. Aqumeldi, an angiotensin-converting enzyme (ACE) inhibitor, manages heart failure in pediatric patients by inhibiting the angiotensin-converting enzyme (ACE), which stops the conversion of angiotensin I to angiotensin II, thus relaxing blood vessels, enhancing blood flow, and easing the heart's workload.

In February 2023, AstraZeneca, a UK-based pharmaceutical company, acquired CinCor Pharma for $1.3 billion. Through this acquisition, AstraZeneca seeks to bolster its cardiorenal pipeline by incorporating CinCor's lead candidate, baxdrostat (CIN-107), a selective aldosterone synthase inhibitor (ASI) aimed at reducing blood pressure in patients with treatment-resistant hypertension. CinCor Pharma, a US-based biopharmaceutical company, focuses on developing renin-angiotensin-system (RAS)-acting agents, including baxdrostat, a selective aldosterone synthase inhibitor for resistant hypertension.

Major companies operating in the renin-angiotensin-system (ras)-acting agents market are Novartis AG, AstraZeneca plc, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Pfizer Inc., Sanofi S.A., Bayer AG, Daiichi Sankyo Company Limited, Astellas Pharma Inc., Biocon Limited, Lupin Limited, Sun Pharmaceutical Industries Ltd., Mylan N.V., Zydus Lifesciences Limited

North America was the largest region in the renin-angiotensin-system (RAS)-acting agents market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the renin-angiotensin-system (ras)-acting agents market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the renin-angiotensin-system (ras)-acting agents market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The renin-angiotensin system (RAS)-acting agents market consists of sales of enalapril, lisinopril, ramipril, and captopril. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Renin-Angiotensin-System (RAS)-Acting Agents Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses renin-angiotensin-system (ras)-acting agents market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for renin-angiotensin-system (ras)-acting agents ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The renin-angiotensin-system (ras)-acting agents market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drug Class: Angiotensin-Converting Enzyme (ACE) Inhibitors; Angiotensin II Receptor Blockers (ARBs); Renin Inhibitors; Aldosterone Antagonists; Other Drug Classes
• 2) By Indication: Hypertension; Heart Failure; Chronic Kidney Disease; Diabetic Nephropathy; Coronary Artery Disease
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Specialty Clinics
• 4) By End-User: Hospitals; Research Institutes; Pharmaceutical Companies; Other End-Users
• Subsegments:
• 1) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Captopril; Enalapril; Lisinopril; Ramipril; Perindopril
• 2) By Angiotensin II Receptor Blockers (ARBs): Losartan; Valsartan; Irbesartan; Olmesartan; Telmisartan
• 3) By Renin Inhibitors: Aliskiren
• 4) By Aldosterone Antagonists: Spironolactone; Eplerenone
• 5) By Other Drug Classes: Dual Angiotensin Receptor-Neprilysin Inhibitors (ARNIs); Vasopeptidase Inhibitors; Mineralocorticoid Receptor Antagonists (MRAs); Angiotensin Receptor Blockers With Neprilysin Inhibitors (ARNBIs)
• Companies Mentioned: Novartis AG; AstraZeneca plc; Boehringer Ingelheim GmbH; Teva Pharmaceutical Industries Ltd.; Sandoz International GmbH; Aurobindo Pharma Limited; Cipla Limited; Dr. Reddy's Laboratories Ltd.; Glenmark Pharmaceuticals Ltd.; Torrent Pharmaceuticals Ltd.; Pfizer Inc.; Sanofi S.A.; Bayer AG; Daiichi Sankyo Company Limited; Astellas Pharma Inc.; Biocon Limited; Lupin Limited; Sun Pharmaceutical Industries Ltd.; Mylan N.V.; Zydus Lifesciences Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Renin-Angiotensin-System (RAS)-Acting Agents Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Renin-Angiotensin-System (RAS)-Acting Agents Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Renin-Angiotensin-System (RAS)-Acting Agents Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Renin-Angiotensin-System (RAS)-Acting Agents Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.3 Artificial Intelligence & Autonomous Intelligence
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Increasing Use Of Combination Antihypertensive Therapies
  • 4.2.2 Growth Of Long-Acting Cardiovascular Drugs
  • 4.2.3 Rising Focus On Renal Protection Therapies
  • 4.2.4 Expansion Of Generic RAS Drug Production
  • 4.2.5 Shift Toward Fixed-Dose Combinations

5. Renin-Angiotensin-System (RAS)-Acting Agents Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Cardiology Clinics
• 5.3 Nephrology Clinics
• 5.4 Retail Pharmacies
• 5.5 Specialty Clinics

6. Renin-Angiotensin-System (RAS)-Acting Agents Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Renin-Angiotensin-System (RAS)-Acting Agents Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Renin-Angiotensin-System (RAS)-Acting Agents PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Renin-Angiotensin-System (RAS)-Acting Agents Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Renin-Angiotensin-System (RAS)-Acting Agents Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Renin-Angiotensin-System (RAS)-Acting Agents Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Renin-Angiotensin-System (RAS)-Acting Agents Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Renin-Angiotensin-System (RAS)-Acting Agents Market Segmentation

• 9.1. Global Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Renin Inhibitors, Aldosterone Antagonists, Other Drug Classes
• 9.2. Global Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hypertension, Heart Failure, Chronic Kidney Disease, Diabetic Nephropathy, Coronary Artery Disease
• 9.3. Global Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics
• 9.4. Global Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Research Institutes, Pharmaceutical Companies, Other End-Users
• 9.5. Global Renin-Angiotensin-System (RAS)-Acting Agents Market, Sub-Segmentation Of Angiotensin-Converting Enzyme (ACE) Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Captopril, Enalapril, Lisinopril, Ramipril, Perindopril
• 9.6. Global Renin-Angiotensin-System (RAS)-Acting Agents Market, Sub-Segmentation Of Angiotensin II Receptor Blockers (ARBs), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Losartan, Valsartan, Irbesartan, Olmesartan, Telmisartan
• 9.7. Global Renin-Angiotensin-System (RAS)-Acting Agents Market, Sub-Segmentation Of Renin Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Aliskiren
• 9.8. Global Renin-Angiotensin-System (RAS)-Acting Agents Market, Sub-Segmentation Of Aldosterone Antagonists, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Spironolactone, Eplerenone
• 9.9. Global Renin-Angiotensin-System (RAS)-Acting Agents Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Dual Angiotensin Receptor-Neprilysin Inhibitors (ARNIs), Vasopeptidase Inhibitors, Mineralocorticoid Receptor Antagonists (MRAs), Angiotensin Receptor Blockers With Neprilysin Inhibitors (ARNBIs)

10. Renin-Angiotensin-System (RAS)-Acting Agents Market Regional And Country Analysis

• 10.1. Global Renin-Angiotensin-System (RAS)-Acting Agents Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Renin-Angiotensin-System (RAS)-Acting Agents Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agents Market

• 11.1. Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agents Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Renin-Angiotensin-System (RAS)-Acting Agents Market

• 12.1. China Renin-Angiotensin-System (RAS)-Acting Agents Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Renin-Angiotensin-System (RAS)-Acting Agents Market

• 13.1. India Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Renin-Angiotensin-System (RAS)-Acting Agents Market

• 14.1. Japan Renin-Angiotensin-System (RAS)-Acting Agents Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Renin-Angiotensin-System (RAS)-Acting Agents Market

• 15.1. Australia Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Renin-Angiotensin-System (RAS)-Acting Agents Market

• 16.1. Indonesia Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Renin-Angiotensin-System (RAS)-Acting Agents Market

• 17.1. South Korea Renin-Angiotensin-System (RAS)-Acting Agents Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Renin-Angiotensin-System (RAS)-Acting Agents Market

• 18.1. Taiwan Renin-Angiotensin-System (RAS)-Acting Agents Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Renin-Angiotensin-System (RAS)-Acting Agents Market

• 19.1. South East Asia Renin-Angiotensin-System (RAS)-Acting Agents Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Renin-Angiotensin-System (RAS)-Acting Agents Market

• 20.1. Western Europe Renin-Angiotensin-System (RAS)-Acting Agents Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Renin-Angiotensin-System (RAS)-Acting Agents Market

• 21.1. UK Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Renin-Angiotensin-System (RAS)-Acting Agents Market

• 22.1. Germany Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Renin-Angiotensin-System (RAS)-Acting Agents Market

• 23.1. France Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Renin-Angiotensin-System (RAS)-Acting Agents Market

• 24.1. Italy Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Renin-Angiotensin-System (RAS)-Acting Agents Market

• 25.1. Spain Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Renin-Angiotensin-System (RAS)-Acting Agents Market

• 26.1. Eastern Europe Renin-Angiotensin-System (RAS)-Acting Agents Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Renin-Angiotensin-System (RAS)-Acting Agents Market

• 27.1. Russia Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Renin-Angiotensin-System (RAS)-Acting Agents Market

• 28.1. North America Renin-Angiotensin-System (RAS)-Acting Agents Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Renin-Angiotensin-System (RAS)-Acting Agents Market

• 29.1. USA Renin-Angiotensin-System (RAS)-Acting Agents Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Renin-Angiotensin-System (RAS)-Acting Agents Market

• 30.1. Canada Renin-Angiotensin-System (RAS)-Acting Agents Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Renin-Angiotensin-System (RAS)-Acting Agents Market

• 31.1. South America Renin-Angiotensin-System (RAS)-Acting Agents Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Renin-Angiotensin-System (RAS)-Acting Agents Market

• 32.1. Brazil Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Renin-Angiotensin-System (RAS)-Acting Agents Market

• 33.1. Middle East Renin-Angiotensin-System (RAS)-Acting Agents Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Renin-Angiotensin-System (RAS)-Acting Agents Market

• 34.1. Africa Renin-Angiotensin-System (RAS)-Acting Agents Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Renin-Angiotensin-System (RAS)-Acting Agents Market Regulatory and Investment Landscape

36. Renin-Angiotensin-System (RAS)-Acting Agents Market Competitive Landscape And Company Profiles

• 36.1. Renin-Angiotensin-System (RAS)-Acting Agents Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Renin-Angiotensin-System (RAS)-Acting Agents Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Renin-Angiotensin-System (RAS)-Acting Agents Market Company Profiles
  • 36.3.1. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Boehringer Ingelheim GmbH Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Sandoz International GmbH Overview, Products and Services, Strategy and Financial Analysis

37. Renin-Angiotensin-System (RAS)-Acting Agents Market Other Major And Innovative Companies

• Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Pfizer Inc., Sanofi S.A., Bayer AG, Daiichi Sankyo Company Limited, Astellas Pharma Inc., Biocon Limited, Lupin Limited, Sun Pharmaceutical Industries Ltd., Mylan N.V., Zydus Lifesciences Limited

38. Global Renin-Angiotensin-System (RAS)-Acting Agents Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Renin-Angiotensin-System (RAS)-Acting Agents Market

40. Renin-Angiotensin-System (RAS)-Acting Agents Market High Potential Countries, Segments and Strategies

• 40.1 Renin-Angiotensin-System (RAS)-Acting Agents Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Renin-Angiotensin-System (RAS)-Acting Agents Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Renin-Angiotensin-System (RAS)-Acting Agents Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer